New drug combo aims to outsmart resistant colon cancer
NCT ID NCT05576896
Summary
This study is testing if adding the drug hydroxychloroquine to two standard cancer drugs helps control advanced colon cancer that has a specific genetic change (BRAF V600E) and has stopped responding to prior treatments. Researchers believe hydroxychloroquine may help overcome the cancer's resistance. The study will enroll about 43 adults to see if the three-drug combination is safe and effective at shrinking tumors and delaying cancer growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.